Nandesari Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 11-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 11-12-2024
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
About Nandesari Drugs And Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vijender Goel, Kanta Goyal, and Ankit Goyal serve as directors at the Company.
- CIN/LLPIN
U24230DL2021PTC384483
- Company No.
384483
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jul 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nandesari Drugs And Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijender Goel  | Director | 30-Jul-2021 | Current |
| Kanta Goyal | Additional Director | 14-Feb-2024 | Current |
| Ankit Goyal | Director | 30-Jul-2021 | Current |
Financial Performance and Corporate Structure Insights of Nandesari Drugs And Pharmaceuticals.
Nandesari Drugs And Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Nandesari Drugs And Pharmaceuticals?
In 2022, Nandesari Drugs And Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Panoli Intermediates (India) Private LimitedActive 26 years 2 monthsVijender Goel and Ankit Goyal are mutual person
Kutch Chemical Industries LimitedActive 22 years 6 monthsVijender Goel and Kanta Goyal are mutual person
_PRIVATE_LIMITED.webp)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nandesari Drugs And Pharmaceuticals?
Nandesari Drugs And Pharmaceuticals has a workforce of 61 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nandesari Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nandesari Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
